Acalabrutinib is a Bruton tyrosine kinase inhibitor used to treat mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.
All Acalabrutinib-related impurity standards are available from Venkatasai, together with certified COAs and characterization data like IR, mass, HPLC, purity, NMR, and TGA reports. In accordance with the regulations, we also offer CMR, DEPT, and thorough structure characterization reports. Major pharmaceutical companies all around the world employ standards connected to Acalabrutinib for their ANDA/DMF applications.